Drug intelligence / Profile preview

nasal air

Development stage: Unknown
Lead developer: Region Skåne
Modality: Small Molecules
Administration: Intranasal, Inhalation

Overview

Nasal air is used as a control intervention in clinical research to evaluate the therapeutic efficacy of supplemental oxygen. In a Phase II study sponsored by Region Skane, nasal air was administered at a flow rate of 3 liters per minute via nasal cannula to patients undergoing percutaneous coronary intervention (PCI) for stable angina or non-ST elevation myocardial infarction (NSTEMI). The study was designed to investigate whether the standard practice of providing supplemental oxygen actually provides superior ischemic pain relief compared to regular air, particularly since oxygen is known to cause coronary artery vasoconstriction and may lack benefit in patients with normal baseline oxygen saturation.

Other names: medical airregular nasal air

Beyond the preview

Go deeper on nasal air.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nasal air.

Explore the full profile